GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| Compound class: 
                                                            Antibody
                                 
                                    
                                        Comment: Zadoprubart is the INN for an anti-B and T lymphocyte attenuator (BTLA) monoclonal antibody. We have been unable to associate this with a clinical candidate or company research code.  There is information confirming two anti-BTLA monoclonals that were progressed to clinical development: HFB200603 (HiFiBiO; Phase 1 NCT05789069, solid tumours) [2] and ANB032 (AnaptysBio; Phase 2 NCT05935085, atopic dermatitis; terminated due to insufficient efficacy) [1]. |